Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma

Journal of Hepatology

Volumn 56, Issue 2, 2012, Pages 486-487

  Garcia, Jairo A ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; SORAFENIB;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; DIARRHEA; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; NOTE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84855979959     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.07.033     Document Type: Note

References (8)

1. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
2. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
3. A.L. Cheng, Y.K. Kang, Z. Chen, C.J. Tsao, S. Qin, and J.S. Kim Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
4. J. Park, R. Finn, and J. Kim Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 17 2011 1973 1983
5. H. Huynh, V.C. Ngo, J. Fargnoli, M. Ayers, K.C. Soo, and H.N. Koong Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma Clin Cancer Res 14 2008 6146 6153
6. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 2008 592 603
7. Raoul J-K, Finn RS, Kang YK, Park J-W, Harris R, Coric V, et al. Phase II, open label study of brivanib alaninate in patients (pts) with hepatocellular carcinoma (HCC) who failed prior antiangiogenic therapy. Presented at: ASCO gastrointestinal cancers symposium, January 15-17, 2009; San Francisco, CA. Abstract 200.
8. G.K. Abou-Alfa, L. Schwartz, S. Ricci, D. Amadori, A. Santoro, and A. Figer Phase II study of sorafenib in patients with advanced hepatocellular carcinoma J Clin Oncol 24 2006 4293 4300 (Pubitemid 46630787)